Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
No vaccine exists for the prevention of infection with the ubiquitous gastric pathogen Helicobacter pylori, and drug therapy for the infection is complicated by poor patient compliance, the high cost of treatment, and ineffectiveness against drug resistant strains. A new medical advancement is required to reduce the incidence of peptic ulcer disease and stomach cancer, two conditions caused by infection with H. pylori. Clinical trials have been performed with a formalin-inactivated Helicobacter pylori Whole Cell (HWC) vaccine, given orally in combination with the mucosal adjuvant mLT(R192G), a mutant of E. coli heat-labile toxin. Following the initial dose of this vaccine, some subjects experienced gastrointestinal side effects. To reduce side effects and potentially further increase the amount of adjuvant that can safely be administered with the HWC vaccine, experiments were performed with a form of LT that carried two mutations in the A subunit, a substitution of G for R at position 192, and A for L at position 211. The double-mutant LT (dmLT) adjuvant stimulated immune responses as effectively as the single mutant LT in mice. Additionally, following a challenge infection, the dmLT-adjuvanted vaccine was as effective as single mutant LT in reducing gastric urease levels (diagnostic for H. pylori infection), and H. pylori colonization in the stomach as assessed by quantitative analysis of stomach homogenates. A lyophilized formulation of HWC was developed to improve stability and to potentially reduce reliance on cold chain maintenance. It was observed that a dmLT-adjuvanted lyophilized vaccine was equally as protective in the mouse model as the liquid formulation as assessed by gastric urease analysis and analysis of stomach homogenates for viable H. pylori. No readily detectable effect of tonicity or moisture content was observed for the lyophilized vaccine within the formulation limits evaluated. In an accelerated stability study performed at 37°C the lyophilized vaccine remained equally as protective as vaccine stored at 2–8°C. The formulation selected for clinical development consisted of 2.5×1010 formalin-inactivated cells per ml in 6.5% trehalose, 0.5% mannitol, and 10 mM citrate buffer at pH 6.8.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cure of duodenal ulcer associated with eradication of Helicobacter pylori
Rauws, E. A. J., & Tytgat, G. N. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91301-p · Cited by 922
Graham, D. Y., Lew, G. M., Klein, P. D., Evans, D. G., Evans, D. J., Saeed, Z. A., & Malaty, H. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-9-705 · Cited by 909
Cited by
Recent progress in mucosal vaccine development: potential and limitations
Lycke, N. (2012) · Nature Reviews Immunology · doi:10.1038/nri3251 · Cited by 807
Current state and challenges in developing oral vaccines
Vela Ramirez, J. E., Sharpe, L. A., & Peppas, N. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.008 · Cited by 412
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Levine, M. M. (2010) · BMC Biology · doi:10.1186/1741-7007-8-129 · Cited by 261
Norton, E. B., Lawson, L. B., Freytag, L. C., & Clements, J. D. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00538-10 · Cited by 221
Self-citation
Metadata
- Authors
- Summerton, N. A., Welch, R. W., Bondoc, L., Yang, H.-H., Pleune, B., Ramachandran, N., Harris, A. M., Bland, D., Jackson, W. J., Park, S., Clements, J. D., & Nabors, G. S.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 28
- Issue
- 5
- Pages
- 1404-1411
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2080614074
- Cited by
- 75
- References
- 2
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. https://app.cochat.ai/papers/10.1016/j.vaccine.2009.10.147
- The paper
- Summerton, N. A., Welch, R. W., Bondoc, L., Yang, H.-H., Pleune, B., Ramachandran, N., Harris, A. M., Bland, D., Jackson, W. J., Park, S., Clements, J. D., & Nabors, G. S. (2010). Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine. https://doi.org/10.1016/j.vaccine.2009.10.147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.